We are live on ! Find out more
MBII

Marrone Bio Innovations, Inc.
MBII

Delisted

MBII was delisted on the 12th of July, 2022.

Back to rankings

19 hedge funds and large institutions have $12.9M invested in Marrone Bio Innovations, Inc. in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $13.6M → $12.9M (-$640K)

17% less funds holding

Funds holding: 23 → 19 (-4)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
19
Holders Change
-4
Holders Change %
-17.39%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$86.3K
2
CPA
Capital Planning Advisors
California
+$11.8K
3
BlackRock
BlackRock
New York
+$3.35K

Top Sellers

Rank Fund Capital Flow
1
ACM
Azimuth Capital Management
Michigan
-$40K
2
Primecap Management
Primecap Management
California
-$30.7K
3
ARTA
A.R.T. Advisors
New York
-$26K
4
VF
Virtu Financial
New York
-$24K
5
SIM
Spark Investment Management
New York
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
WRF
1
Waddell & Reed Financial
Kansas
$5.19M – – –
AAP
2
Ardsley Advisory Partners
Connecticut
$4.05M – – –
Primecap Management
3
Primecap Management
California
$2.89M -$30.7K -30,000 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$521K +$86.3K +84,377 +22%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$98K – – –
BlackRock
6
BlackRock
New York
$87K +$3.35K +3,272 +4%
Northern Trust
7
Northern Trust
Illinois
$27K – – –
CPA
8
Capital Planning Advisors
California
$13K +$11.8K +11,500 New
RJFSA
9
Raymond James Financial Services Advisors
Florida
$12K -$5.11K -5,000 -31%
State Street
10
State Street
Massachusetts
$12K – – –
AWS
11
AJ Wealth Strategies
New York
$11K -$4.69K -4,587 -31%
AF
12
Allworth Financial
California
$11K – – –
UBS Group
13
UBS Group
Switzerland
$4K -$3.91K -3,825 -49%
GBBWRPM
14
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$4K – – –
LTFS
15
Ladenburg Thalmann Financial Services
Florida
$3K – – –
Morgan Stanley
16
Morgan Stanley
New York
$1K – – –
FDCDDQ
17
Federation des caisses Desjardins du Quebec
Quebec, Canada
$550 – – –
ACM
18
Azimuth Capital Management
Michigan
– -$40K -35,000 Closed
ARTA
19
A.R.T. Advisors
New York
– -$26K -23,171 Closed
VF
20
Virtu Financial
New York
– -$24K -20,446 Closed
SIM
21
Spark Investment Management
New York
– -$15K -13,400 Closed
TSS
22
Two Sigma Securities
New York
– -$13K -11,088 Closed

MBII Hedge Fund Activity: Q4 2017 in Review

19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Marrone Bio Innovations, Inc. (MBII) for Q4 2017, worth a combined $12.9M — down 4.7% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MBII and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $86.3K. The largest seller was Azimuth Capital Management, exiting entirely with an estimated $40K sold.

  • 19 institutional investors held Marrone Bio Innovations, Inc. (MBII) as of Q4 2017, down from 23 in Q3 2017.
  • Funds reported $12.9M of Marrone Bio Innovations, Inc. stock for Q4 2017, down 4.7% quarter-over-quarter.
  • 1 fund opened new Marrone Bio Innovations, Inc. positions in Q4 2017 and 5 closed out, a net change of -4 holders.
  • The largest Marrone Bio Innovations, Inc. buyer in Q4 2017 was Vanguard Group, an estimated $86.3K added.
  • The largest Marrone Bio Innovations, Inc. seller in Q4 2017 was Azimuth Capital Management, an estimated $40K sold.

Based on aggregated 13F filings for Q4 2017.